Literature DB >> 7884149

Toxicological evaluation of mu-agonists. Part I: Assessment of toxicity following 30 days of repeated oral dosing of male and female rats with levo-alpha-acetylmethadol HCl (LAAM).

J F Borzelleca1, J L Egle, L S Harris, D N Johnson, J B Terrill, J A Belleville.   

Abstract

This study evaluated levo-alpha-acetylmethadol hydrochloride (LAAM), a long-acting morphine-like (mu) agonist approved in 1993 to treat opiate dependence. Sprague-Dawley rate (20/sex/group) were gavaged with doses of 3.0-33.5 mg kg-1 for 30 days followed by a 14-day drug-free recovery period. Treatment-related effects included dose-dependent CNS depression, decreased food consumption and body weight gain, reddish urine and abdominal staining. Tolerance developed by day 7. Mortality was dose-dependent; deaths occurred predominantly during the first week. Increased alanine aminotransferase (SGOT, AST) and lactate dehydrogenase (LDH), observed only in high-dose males, were associated with findings in liver. Decreases in spleen/brain weight and increases in brain/body weight ratios were seen in both sexes. Decreases in weights of heart, liver and kidney achieved statistical significance only for high-dose groups. Kidneys of mid- and high-dose groups displayed intertubular mineral/crystal deposition, focal corticomedullary mineralization and focal regenerative tubular epithelium. Centrilobular hypertrophy was observed in livers of high-dose males and mid- and high-dose females. Following the recovery period, decreased body weights and increased brain/body weight ratios occurred in mid-dose males and low-dose females. Weights of liver and kidney and organ/brain weight ratios were decreased in mid-dose males. Histopathological findings observed in kidneys and livers had abated. In summary, acute and repeated administration of LAAM produced a spectrum of activity consistent with its profile as a long-acting pure mu-agonist which stimulates microsomal enzymes in rodents. Renal and hepatic effects seen in initially drug-naive rats treated with morphine-type agonists are not observed in tolerant individuals stabilized on mu-agonists to treat opiate dependence.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7884149     DOI: 10.1002/jat.2550140609

Source DB:  PubMed          Journal:  J Appl Toxicol        ISSN: 0260-437X            Impact factor:   3.446


  5 in total

1.  Liver and kidney toxicity in chronic use of opioids: an experimental long term treatment model.

Authors:  Sebnem Atici; Ismail Cinel; Leyla Cinel; Nurcan Doruk; Gulcin Eskandari; Ugur Oral
Journal:  J Biosci       Date:  2005-03       Impact factor: 1.826

2.  Role of oxidative stress in celecoxib-induced renal damage in wistar rats.

Authors:  Shikha Gupta; Pooja Sarotra; Ritu Aggarwal; Nisha Dutta; Navneet Agnihotri
Journal:  Dig Dis Sci       Date:  2007-03-31       Impact factor: 3.199

3.  Opium use and risk of mortality from digestive diseases: a prospective cohort study.

Authors:  Masoud M Malekzadeh; Hooman Khademi; Akram Pourshams; Arash Etemadi; Hossein Poustchi; Mohammad Bagheri; Masoud Khoshnia; Amir Ali Sohrabpour; Ali Aliasgari; Elham Jafari; Farhad Islami; Shahryar Semnani; Christian C Abnet; Paul D P Pharoah; Paul Brennan; Paolo Boffetta; Sanford M Dawsey; Reza Malekzadeh; Farin Kamangar
Journal:  Am J Gastroenterol       Date:  2013-10-22       Impact factor: 10.864

4.  Opium use and mortality in Golestan Cohort Study: prospective cohort study of 50,000 adults in Iran.

Authors:  Hooman Khademi; Reza Malekzadeh; Akram Pourshams; Elham Jafari; Rasool Salahi; Shahryar Semnani; Behrooz Abaie; Farhad Islami; Siavosh Nasseri-Moghaddam; Arash Etemadi; Graham Byrnes; Christian C Abnet; Sanford M Dawsey; Nicholas E Day; Paul D Pharoah; Paolo Boffetta; Paul Brennan; Farin Kamangar
Journal:  BMJ       Date:  2012-04-17

Review 5.  Morphine for the treatment of pain in sickle cell disease.

Authors:  Mihir Gupta; Lilian Msambichaka; Samir K Ballas; Kalpna Gupta
Journal:  ScientificWorldJournal       Date:  2015-01-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.